Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus + sirolimus versus cyclosporine + methotrexate for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation
2006-006577-25Phase 3Completed
- Sponsor
- Karolinska Institutet
- Start
- Jun 2007
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in graft-versus-host disease (GVHD) comparing Tacrolimus + sirolimus with Cyclosporine + methotrexate (2 arms). Primary endpoint: Grade II-IV acute graft-versus-host disease. Started Jun 2007; status: completed.
02
Drugs
tacrolimussirolimuscyclosporinemethotrexate
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on 2006-006577-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006577-25.